- News Feature : Surviving in the market space [10/07/2020 - Fiji]
- Sports News : 14 more sports accredited in Fiji [10/07/2020 - Fiji]
- News Feature : Protecting the human rights of migrants in the Pacific essential in COVID-19 recovery process, UN agencies say [10/07/2020 - Fiji]
- Business News : Hopes for a Pacific travel bubble fading [10/07/2020 - Fiji]
- Business News : From relief to Recovery: PNG's economy in the time of COVID-19 [10/07/2020 - Papua New Guinea]
- News : COVID-19: Fiji records additional five border control cases [10/07/2020 - Fiji]
- News : Fiji's ratification of the nuclear treaty calls for new clear ways [10/07/2020 - Fiji]
- News : "It's going to happen again," says former New Zealand PM Clark tasked with WHO COVID-19 review [10/07/2020 - New Zealand]
- News : Tearful WHO director calls for global unity to fight the virus following U.S. pullout [10/07/2020 - Switzerland]
- News : Tahiti may host meeting to elect new PIF head [10/07/2020 - French Polynesia]
- News : Trachoma intervention reaches 8024 Nauruans [10/07/2020 - Nauru]
- News Feature : Pacific Climate Change study gains $4.5million [10/07/2020 - New Zealand]
- Sponsored : Oceania National Olympic Committees (ONOC)
The World Health Organisation has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.
Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The U.S. President has said he was taking the drug to help prevent infection.
“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.
He said the other arms of the trial - a major international initiative to hold clinical tests of potential treatments for the virus - were continuing.
The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.
Dr Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution.
Pacific Islands News Association
Who & What is PINA?
International News Safety Institute (INSI)
Media Helping Media